FormBlends Launches Comprehensive GLP-1 and Peptide Intelligence Platform

New platform aims to provide patients with transparent, evidence-based information on weight management medications.

Apr. 9, 2026 at 12:08pm by Ben Kaplan

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the intricate internal structures of a human pancreas, glowing with a faint blue-green bioluminescence and conceptually representing the complex biological processes involved in GLP-1 and peptide therapies.As the market for GLP-1 and peptide weight loss medications surges, a new platform aims to shed light on the complex biological mechanisms behind these fast-growing treatments.San Francisco Today

FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, has announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States.

Why it matters

As the $45 billion GLP-1 market accelerates toward $122 billion by 2030, FormBlends is building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education to address an information crisis in the fastest-growing drug category.

The details

The platform now features 7,282 individually profiled provider listings across all 50 states, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering every major GLP-1 and peptide therapy on the market. FormBlends aims to close the widening gap between what consumers need to know and what they can reliably find online about these fast-growing treatments.

  • FormBlends announced the platform expansion on April 9, 2026.
  • The global GLP-1 receptor agonist market reached $45.3 billion in 2025 and is projected to hit $122.3 billion by 2030.
  • Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new 'Medicare GLP-1 Bridge' program.

The players

FormBlends

A health technology platform focused on GLP-1 weight loss results and weight management provider directory listings.

Got photos? Submit your photos here. ›

What’s next

The FormBlends platform is available now at formblends.com. All educational content, research reports, interactive tools, and provider directory listings are free to access. Patients interested in exploring whether physician-supervised treatment may be appropriate for their circumstances can begin with a free health assessment.

The takeaway

As the market for GLP-1 and peptide weight loss medications continues to grow rapidly, FormBlends is positioning itself as the definitive consumer resource for evidence-based information, provider transparency, and clinical education to help patients navigate this fast-evolving treatment landscape.